SavedAdd your journal

Journals / Ankara Medical Journal / 2016 / Cilt: 16 - Sayı: 2

The Use of Pharmacogenetic Knowledge in Gastroenterology

Gastroenteroloji Alanında Farmakogenetik Bilginin Kullanılması

Halil KARA
Mustafa Tuğrul GÖKTAŞ
Pages
232–238
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, we aimed to discuss how the proton pump inhibitors are affected by CYP2C19 gene-polymorphisims and its clinical aspects

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pharmacogenetic is the science explaining inter-individual variability and variability among ethnic groups for drug responses and the related reasons.
📊
Key Findings & Data:This failure may be mostly caused by genetic variations in P450(CYP) that coordinates the metabolism of drug.
💡
Conclusion & Impact:In this paper, we aimed to discuss how the proton pump inhibitors are affected by CYP2C19 gene-polymorphisims and its clinical aspects
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Pharmacogenetic is the science explaining inter-individual variability and variability among ethnic groups for drug responses and the related reasons. Genetic variances might lead side effects besides improper drug response or failed treatment. All clinicians aim to apply correct treatment to patients using correct medication for proper period. However this is not always possible. This failure may be mostly caused by genetic variations in P450(CYP) that coordinates the metabolism of drug. Therefore, enzymes that play role in the metabolism of drugs applied to patients and genetic variations of the patients should be known. In this paper, we aimed to discuss how the proton pump inhibitors are affected by CYP2C19 gene-polymorphisims and its clinical aspects

Özet

İlaçlara karşı elde edilen yanıtların bireyler veya etnik gruplar arasındaki farklılıklarının nedenini açıklayan araştırma alanı farmakogenetik bilimidir. Genetik farklılıklar nedeniyle ilaçlardan istenen yanıt elde edilemeyeceği gibi, bir takım yan etkiler de ortaya çıkabilir. Hekim olarak en çok arzu ettiğimiz konuların başında, hastamızın doğru ilaçla, doğru sürede tedavisinin gerçekleşmesini sağlamak gelmektedir. Fakat bu her zaman mümkün olmamaktadır. Bu başarısızlığın en önemli sebeplerinden biri de ilaçların metabolizmasında rol alan sitokrom P450 (CYP) enzimlerindeki genetik değişikliklerdir. Dolayısıyla hastalara uygulayacağımız ilaçların hangi enzimler aracılığı ile metabolize edildiğini ve hastaların genetik özelliklerini bilmek önem kazanmaktadır. Bu makalede özellikle gastroenteroloji alanında kullanılan proton pompa inhibitörlerinin CYP2C19 gen polimorfizminden nasıl etkilendiği ve klinik yansımaları tartışılmıştır

🔖

Cite This Article

KARA, H., GÖKTAŞ, M. T. (2022). The Use of Pharmacogenetic Knowledge in Gastroenterology. Ankara Medical Journal, Cilt: 16 - Sayı: 2, 232–238. https://ajindex.com/articles/442075

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133(3):985-1001.
  2. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996;25(2):373-96.
  3. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347(15):1175-86. Forman D. Helicobacter pylori and gastric cancer. Scand J Gastroenterol Suppl 1996; 220:23-6. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1(8336):1273-5.
  4. O'Connor A, Molina-Infante J, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter 2013;18(1):58-65. Dixon MF. Pathology of Gastritis and Peptic Ulceration. in Helicobacter pylori: Physiology and Genetic. Mobley HLT, Mendz GL, Hazell SL (Editors),Washington (DC): ACM Press; 2001. Baron JH. The history of acid inhibition. Yale J Biol Med 1994;67(3-4):97-106.
  5. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013;19(1):25-35.
  6. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008;10(6):528-34. Özden A. Hp'nin 30. Yılı (1983-2013) Helicobacter pylori Eradikasyonunda Proton Pompa İnhibitörlerinin Yarattığı Mucize Güncel Gastroenteroloji 2013; 17(2): 119-131.
  7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-5.
  8. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007;1770(3):489-94. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009;48(11):689-723. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007; 46(4): 271-9.
  9. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64(10):935-51. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52(4):349-55.
  10. Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 2008;65(5):752-60.
  11. Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S,